MedTrace Logo

Tafenoquine/Chloroquine DDI Study

NCT00871156 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-06-19

No results posted yet for this study

Summary

DDI study of Tafenoquine and Chloroquine

Conditions

Interventions

DRUG

Chloroquine, Tafenoquine

Chloroquine and Tafenoquine

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Medicines for Malaria Venture

    collaborator OTHER

  • GlaxoSmithKline

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-24
Primary Completion
2009-08-26
Completion
2009-08-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871156 on ClinicalTrials.gov